Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1733- SFN,    Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal
- in-vitro, PC, PanCSC - in-vitro, Nor, HPNE - in-vitro, Nor, HNPSC
CSCs↓, Shh↓, Gli↓, Nanog↓, OCT4↓, PDGFRA↓, cycD1/CCND1↑, Apoptosis↑, Casp↑, Smo↓, Gli1↓, GLI2↓, Bcl-2↓, Casp3↑, Casp7↑,
1734- SFN,    Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia
- in-vitro, Bladder, RT112
selectivity↑, TumCP↓, Glycolysis↓, Hif1a↓,
1735- SFN,    Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane
- in-vitro, GBM, T98G - in-vitro, GBM, U87MG
Apoptosis↑, Ca+2↑, Bax:Bcl2↑, cal2↑, Casp12↑, Casp9↑, Cyt‑c↑,
1736- SFN,    Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models
- in-vitro, BC, NA - in-vivo, BC, NA
TumCG↓, selectivity↓,
1727- SFN,    Glucoraphanin, sulforaphane and myrosinase activity in germinating broccoli sprouts as affected by growth temperature and plant organs
- Analysis, Nor, NA
eff↑, eff↓,
1726- SFN,    Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential
- Review, Var, NA
Dose↝, eff↝, IL1β↓, IL6↓, IL12↓, TNF-α↓, COX2/PTGS2↓, CXCR4↓, MPO↓, HSP70/HSPA5↓, HSP90↓, VCAM-1↓, IKKα↓, NF-kB↓, HO-1↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, CHOP/DDIT3↑, survivin↓, XIAP↓, p38↑, Fas↑, PUMA↑, VEGF↓, Hif1a↓, Twist↓, Zeb1↓, Vim↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Snail↓, CD44↓, cycD1/CCND1↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, CDK4↓, CDK6↓, p50↓, P53↑, P21↑, GSH↑, SOD↑, GSTs↑, mTOR↓, Akt↓, PI3K↓, β-catenin/ZEB1↓, IGF-1↓, cMyc↓, CSCs↓,
1725- SFN,    Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway
- Review, Var, NA
*toxicity∅, AntiCan↑, antiOx↑, NRF2↑, DNMTs↓, HDAC↓, Hif1a↓, VEGF↓, P21↑, TumCCA↑, ac‑H3↑, ac‑H4↑, DNAdam↑, Dose↝,
1724- SFN,    Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials
- Review, Var, NA
antiOx↑, NRF2↑, HDAC↓, neuroP↑,
1723- SFN,    Sulforaphane as a potential remedy against cancer: Comprehensive mechanistic review
- Review, Var, NA
*NRF2↑, ROS↑, MMP↓, Cyt‑c↑, cl‑PARP↑, Apoptosis↑, AMPK↑, GSH↓,
1722- SFN,    Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems
- Review, Var, NA
TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,
3947- Shank,    Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer's disease Drosophila model
- in-vivo, AD, NA
*OS↑, *antiOx↑, *ROS↓, *AChE↑, *neuroP↑, *memory↑,
3948- Shank,    Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain
- in-vivo, AD, NA
*AChE↓, *ChAT↑, *NGF↑, *CDK5↓, *neuroP↑, *MDA↓,
3946- Shank,    Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies
- Review, AD, NA
*neuroP↑, *cognitive↑, *AChE↓, *antiOx↑, *GSR↑, *SOD↑, *GSH↑, *Inflam↓, *ROS↓, *lipid-P↓, *cardioP↑,
3945- Shank,    Novel insights on acetylcholinesterase inhibition by Convolvuluspluricaulis, scopolamine and their combination in zebrafish
- in-vivo, AD, NA
*AChE↓,
3944- Shank,    Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies
- Review, AD, NA
*memory↑, *neuroP↑, *Inflam↓, *5HT↑,
3943- Shank,    Protective Mechanisms of Nootropic Herb Shankhpushpi (Convolvulus pluricaulis) against Dementia: Network Pharmacology and Computational Approach
- Review, AD, NA
*neuroP↑, *memory↑, *other↝, *AChE↓, *MAOA↓, *MAOB↓, *TrkB↓, *tau↓, *APP↓, *ROS↓, *Mood↑,
4203- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders
- Review, NA, NA
*MAPK↝, *AMPK↝, *NF-kB↓, *mTOR↝, *PI3K↝, *Akt↝, *BioAv↝, *memory↑, *BDNF↑, *TNF-α↓,
4204- SIL,    Silymarin administration after cerebral ischemia improves survival of obese mice by increasing cortical BDNF and IGF1 levels
- NA, Stroke, NA
*OS↑, *BDNF↑, *IGF-1↑,
3300- SIL,    Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy
- Review, Var, NA
*ROS↓, *SOD↑, *hepatoP↑, *AST↓, *ALAT↓, *lipid-P↓, *GSH↑, *Catalase↑, *GSTs↑, *GSR↑, *TNF-α↓, *IFN-γ↓, *IL4↓, *IL2↓, *NF-kB↓, *IL10↑, *Inflam↓, COX2/PTGS2↓, Apoptosis↑, ChemoSen↑, PGE2↓, VEGF↓,
3312- SIL,    Silymarin Alleviates Oxidative Stress and Inflammation Induced by UV and Air Pollution in Human Epidermis and Activates β-Endorphin Release through Cannabinoid Receptor Type 2
- Human, Nor, NA
*antiOx↑, *Inflam↓, *ROS↓, *IL1α↓, *AhR↑, *NRF2↑, *IL8↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2/PTGS2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3302- SIL,    Protective effects of silymarin in glioblastoma cancer cells through redox system regulation
- in-vitro, GBM, U87MG
NRF2↑, HO-1↑, Trx↑, antiOx↑,
3303- SIL,    Exploring the anti-cancer and antimetastatic effect of Silymarin against lung cancer
- Review, Var, NA
chemoP↑, radioP↑,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,
3307- SIL,    Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications
- Review, Var, NA
*NRF2↑, *antiOx↑, *chemoP↑, *Inflam↓, *BioAv↑, eff↑, *NQO1↑, TNF-α↓, IL6↓, *GSH↑, *ROS↓, *MDA↓, eff↑, *hepatoP↑, *GPx↑, *SOD↑, *Catalase↑, *HO-1↑, *neuroP↑,
3308- SIL,    Structural basis of Nrf2 activation by flavonolignans from silymarin
- Analysis, NA, NA
*antiOx↑, *chemoP↑, *NRF2↑,
3309- SIL,    Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
- Review, NA, NA
*ROS↓, *IronCh↑, *MMP↑, *NRF2↑, *Inflam↓, *hepatoP↑, *HSPs↑, *Trx↑, *SIRT2↑, *GSH↑, *ROS↑, *NADPH↓, *iNOS↓, *NF-kB↓, *BioAv↓, *Dose↝, *BioAv↑,
3310- SIL,    Silymarin attenuates paraquat-induced lung injury via Nrf2-mediated pathway in vivo and in vitro
- in-vitro, Lung, A549
Inflam↓, MPO↓, NO↓, iNOS↓, ROS↓, MDA↑, SOD↑, Catalase↑, GPx↑, NRF2↑, HO-1↑, NADPH↑,
3311- SIL,    Silymarin protects against acrylamide-induced neurotoxicity via Nrf2 signalling in PC12 cells
- in-vitro, Nor, PC12
*antiOx↑, *Inflam↓, AntiCan↑, *ROS↓, *MDA↓, *GSH↓, *NRF2↑, *GPx↑, *GCLC↑, *GCLM↑,
3299- SIL,    Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells
- in-vitro, Colon, HT29
tumCV↓, MMP↓, ROS↑, selectivity↑,
3298- SIL,    Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells
- in-vitro, BC, MCF7
LC3II↑, Beclin-1/ATG6↑, Bcl-2↓, ROS↑, MMP↓, ATP↓, eff↓, BNIP3?, TumAuto↑, eff↑,
3297- SIL,  Rad,    Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells
- in-vitro, CRC, HCT15 - in-vitro, CRC, RKO
TumCP↓, RadioS↑, TumCCA↑, DNAdam↓, MMP↓, ROS↓, *radioP↑,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3295- SIL,    Hepatoprotective effect of silymarin
- Review, NA, NA
*hepatoP↑, *ROS↓, *GSH↑, *BioAv↝, ERK↓, NF-kB↓, STAT3↓, COX2/PTGS2↓, Inflam↓, IronCh↑, lipid-P↓, ALAT↓, AST↓, TNF-α↓, *α-SMA↓, *SOD↑,
3294- SIL,    Silymarin: a review on paving the way towards promising pharmacological agent
- Review, Nor, NA - Review, Arthritis, NA
*hepatoP↑, *Inflam↓, *chemoP↑, *glucose↓, *antiOx↑, *ROS↓, *ACC↓, *FASN↓, *radioP↑, *NF-kB↓, *TGF-β↓, *AST↓, *α-SMA↝, *eff↑, *neuroP↑, eff↑, ROS↓,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3292- SIL,  Fe,    Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study
- in-vitro, BC, 4T1 - in-vivo, BC, 4T1
*antiOx↑, ROS↑, OS↑, Weight↑, TumVol↓, eff↑, Fenton↑,
3291- SIL,    Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases
- Review, Nor, NA
*antiOx↑, *ROS↓, *cardioP↑, *BioAv↓, *Half-Life↝, *other↑, IronCh↑,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2/PTGS2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27/CDKN1B↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31/PECAM-1↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2/PTGS2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1/SREBF1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3647- SIL,    Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation
- in-vivo, NA, NA
*IL1β↓, *GutMicro↝, *Inflam↓,
3655- SIL,    Protective effect of silymarin on oxidative stress in rat brain
- in-vivo, AD, NA
*GSH↑, *VitC↑, *SOD↑, *lipid-P↓, *ROS↓, *hepatoP↑, *neuroP↑,
3654- SIL,    Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain
- in-vivo, AD, NA
*ROS↓, *neuroP↑, *GSH↑, *SOD↑,
3653- SIL,    Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress
- in-vivo, AD, NA
*hepatoP↑, *neuroP↑, *cognitive↑, *memory↑, *Inflam↓, *GSH↑, *MDA↓, *Inflam↓, *antiOx↓,
3652- SIL,    Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus
- in-vivo, NA, NA
*hepatoP↑, *other↑,
3651- SIL,    Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
- Trial, NA, NA
*hepatoP↑, *ALAT↓,

Showing Research Papers: 7401 to 7450 of 8276
Prev Page 149 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8276

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 1,   CYP1A1↓, 2,   Fenton↑, 1,   GPx↑, 1,   GSH↓, 3,   GSH↑, 2,   GSTs↑, 1,   HO-1↑, 4,   lipid-P↓, 3,   MDA↑, 1,   MPO↓, 2,   NRF2↑, 4,   ROS↓, 4,   ROS↑, 9,   SOD↓, 1,   SOD↑, 2,   SOD1↓, 1,   SOD2↓, 1,   Trx↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   MEK↓, 1,   MMP↓, 7,   Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   cMyc↓, 4,   CYP3A4↓, 1,   Glycolysis↓, 1,   NADPH↑, 1,   SIRT1↓, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Akt↑, 1,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 9,   BAX↑, 8,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   Bcl-2↑, 1,   Bcl-xL↓, 3,   BIM↓, 1,   Casp↑, 3,   Casp12↑, 1,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp7↑, 2,   Casp8↑, 1,   pro‑Casp8↑, 1,   Casp9↑, 7,   Cyt‑c↑, 7,   Diablo↑, 1,   DR5↑, 1,   FADD↑, 1,   Fas↑, 2,   FasL↑, 1,   iNOS↓, 2,   p‑JNK↓, 1,   p‑JNK↑, 3,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 3,   p27/CDKN1B↑, 2,   p38↑, 1,   p‑p38↓, 2,   p‑p38↑, 2,   PUMA↑, 1,   survivin↓, 6,   Telomerase↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↑, 2,   p‑pRB↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   BNIP3?, 1,   LC3II↑, 2,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 2,   DNAdam↑, 1,   DNMTs↓, 1,   P53↑, 6,   cl‑PARP↑, 6,   PCNA↓, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK4↓, 3,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 4,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 2,   P21↑, 4,   RB1↑, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 2,   CSCs↓, 3,   EMT↓, 4,   ERK↓, 4,   p‑ERK↓, 4,   FOXM1↓, 1,   Gli↓, 1,   Gli1↓, 1,   HDAC↓, 5,   IGF-1↓, 1,   IGFBP3↑, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   Nanog↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   p‑P70S6K↓, 1,   PDGFRA↓, 1,   PI3K↓, 3,   Shh↓, 1,   Smo↓, 1,   STAT3↓, 5,   TumCG↓, 3,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   CA↓, 1,   Ca+2↑, 2,   cal2↑, 1,   CD31/PECAM-1↓, 1,   E-cadherin↑, 4,   FAK↓, 1,   GLI2↓, 1,   miR-203↑, 1,   MMP2↓, 3,   MMP9↓, 3,   MMPs↓, 1,   N-cadherin↓, 3,   PDGF↓, 1,   Snail↓, 1,   TGF-β↓, 2,   TumCI↓, 2,   TumCMig↓, 4,   TumCP↓, 4,   TumMeta↓, 3,   Twist↓, 1,   uPA↓, 2,   VCAM-1↓, 1,   Vim↓, 4,   Zeb1↓, 2,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   EGFR↓, 2,   Hif1a↓, 8,   LOX1↓, 1,   NO↓, 1,   VEGF↓, 7,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 6,   CXCR4↓, 4,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IL1↓, 2,   IL10↓, 1,   IL12↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 3,   Inflam↓, 7,   MDSCs↓, 1,   NF-kB↓, 5,   p50↓, 1,   PD-L1↓, 1,   PGE2↓, 3,   PSA↓, 2,   TNF-α↓, 4,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   ChemoSen↑, 2,   Dose↝, 5,   eff↓, 2,   eff↑, 12,   eff↝, 2,   Half-Life↓, 1,   Half-Life↝, 2,   RadioS↑, 2,   selectivity↓, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AR↓, 1,   AST↓, 1,   EGFR↓, 2,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 3,   PD-L1↓, 1,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   cardioP↑, 2,   chemoP↑, 6,   hepatoP↑, 4,   neuroP↑, 2,   OS↑, 1,   radioP↑, 4,   toxicity?, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 3,   Weight↑, 1,  
Total Targets: 215

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 11,   Catalase↑, 2,   GCLC↑, 1,   GCLM↑, 1,   GPx↑, 2,   GSH↓, 1,   GSH↑, 8,   GSR↑, 2,   GSTs↑, 2,   HO-1↑, 1,   lipid-P↓, 4,   MDA↓, 4,   NQO1↑, 1,   NRF2↑, 6,   ROS↓, 15,   ROS↑, 1,   SOD↑, 6,   Trx↑, 1,   VitC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   ALAT↓, 2,   AMPK↝, 1,   FASN↓, 1,   glucose↓, 1,   NADPH↓, 1,   SIRT1↑, 1,   SIRT2↑, 1,  

Cell Death(tgid=5) ⓘ

AhR↑, 1,   Akt↝, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 2,   other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSPs↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↑, 1,   mTOR↝, 1,   PI3K↝, 1,  

Migration(tgid=13) ⓘ

APP↓, 1,   CDK5↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   α-SMA↓, 1,   α-SMA↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↓, 1,   IL10↑, 1,   IL1α↓, 1,   IL1β↓, 1,   IL2↓, 1,   IL4↓, 1,   IL8↓, 2,   Inflam↓, 13,   NF-kB↓, 4,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 4,   AChE↑, 1,   BDNF↑, 2,   ChAT↑, 1,   MAOA↓, 1,   NGF↑, 1,   tau↓, 1,   TrkB↓, 1,  

Protein Aggregation(tgid=19) ⓘ

MAOB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 2,   BioAv↝, 3,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   GutMicro↝, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   chemoP↑, 3,   cognitive↑, 2,   hepatoP↑, 10,   memory↑, 5,   Mood↑, 1,   neuroP↑, 10,   OS↑, 2,   radioP↑, 2,   toxicity↓, 1,   toxicity∅, 2,  
Total Targets: 87

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page